Literature DB >> 2940965

Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora.

T Bergan, C Delin, S Johansen, I M Kolstad, C E Nord, S B Thorsteinsson.   

Abstract

The pharmacokinetics of ciprofloxacin was studied in 12 volunteers during a 5-day course of 500 mg of ciprofloxacin given orally twice a day. The effects on the microflora of saliva and feces were also examined. Serum and urine samples were assayed for ciprofloxacin microbiologically, and the salivary and fecal microflora were examined quantitatively after processing onto a series of selective media. Fecal samples were also investigated for the presence of Clostridium difficile and its cytotoxin. The MICs for new colonizing bacteria were examined in the salivary and fecal samples. There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter). The serum half-life was 2.5 h on both days. The changes in the salivary flora were minor and affected only the neisseriae. In the fecal flora, the numbers of enterobacteria and enterococci decreased markedly, whereas the changes in anaerobic flora (anaerobic cocci, fusobacteria, and bacteroids) were not so pronounced. However, 14 days after the drug was discontinued, the salivary and fecal flora were normalized in all respects. No new colonization of ciprofloxacin-resistant bacteria for which MICs were above 1.0 mg/liter was observed. C. difficile or its cytotoxin was not detected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940965      PMCID: PMC176395          DOI: 10.1128/AAC.29.2.298

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  [The action of ampicillin on the intestinal flora in healthy subjects].

Authors:  H Knothe; B Wiedemann
Journal:  Zentralbl Bakteriol Orig       Date:  1965-08

Review 2.  Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections.

Authors:  C E Nord; L Kager; A Heimdahl
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

3.  Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora.

Authors:  B Kemmerich; H Warns; H Lode; K Borner; P Koeppe; H Knothe
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

4.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man.

Authors:  A Heimdahl; C E Nord
Journal:  Scand J Infect Dis       Date:  1979

6.  A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.

Authors:  L Shrire; J Saunders; R Traynor; H J Koornhof
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

10.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

View more
  25 in total

1.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Clinical role of the quinolones today and in the future.

Authors:  F A Waldvogel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

5.  Pharmacokinetics of ciprofloxacin in cystic fibrosis.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; L Heggen; D Stempel; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

6.  Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects.

Authors:  E A Piercy; R E Bawdon; P A Mackowiak
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 7.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Comparison of ceftriaxone, amikacin, and ciprofloxacin in treatment of experimental Yersinia enterocolitica O9 infection in mice.

Authors:  M Jiménez-Valera; C Gonzalez-Torres; E Moreno; A Ruiz-Bravo
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.